Intracranial Control Seen With Dato-DXd in NSCLC Brain Metastasis Subgroups


Phase 2 data support further evaluation of datopotamab deruxtecan in patients with non–small cell lung cancer and brain metastases.

“The data support further investigation of Dato-DXd in patients with brain [metastases],” according to the study investigators.

“The data support further investigation of Dato-DXd in patients with brain [metastases],” according to the study investigators.

Encouraging intracranial activity occurred in previously treated patients with advanced or metastatic non–small cell lung cancer (NSCLC) following therapy with datopotamab deruxtecan (Dato-DXd), according to exploratory analysis data from the phase 2 TROPION-Lung05 trial (NCT04484142) presented during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.

“This is the first data to suggest [intracranial] antitumor activity with Dato-DXd in patients with heavily pretreated [advanced/metastatic] NSCLC,” the investigators wrote in their poster presentation of the data.

Overall Response to Dato-DXd

In the post hoc analysis, at the data cutoff of December 14, 2022, 53 patients with baseline brain metastases demonstrated an overall response rate (ORR) of 28% (95% CI, 17%-42%), including no complete responses (CRs), 28% with partial responses (PRs), 40% with stable disease (SD), and 19% with progressive disease (PD). In the group of 84 patients without baseline brain metastases, ORR was 40% (95% CI, 30%-52%), including 5% with CRs, 36% with PRs, 42% with SD, and 11% with PD.

In addition, the disease control rate (DCR) for those with baseline brain metastases was 72% (95% CI, 58%-83%) and 83% (95% CI, 74%-91%) for those without. Similarly, clinical benefit rates (CBR) were 40% (95% CI, 27%-54%) and 51% (95% CI, 40%-62%), respectively.

Median progression-free survival (PFS) was 5.4 months (95% CI, 3.1-7.0) for patients with baseline brain metastases and 5.6 months (95% CI, 4.9-8.3) for those without.

Intracranial Efficacy

When evaluating intracranial efficacy, the ORR for the 18 evaluable patients with baseline brain metastases was 22% (95% CI, 6%-48%), including 18% (95% CI, 2%-52%) for the EGFR-mutated subgroup (n = 11), 29% (95% CI, 4%-71%) for the non-EGFR-mutated subgroup (n = 7), and 20% (95% CI, 1%-72%) for the ALK rearrangement subgroup (n = 5).

Of note, among the 3 patients with brain metastasis target lesions who did not undergo previous local therapy, 1 patient experienced central nervous system response (ORR, 33%).

Among these 18 patients, DCR was 72% (95% CI, 47%-90%) and CBR was 44% (95% CI, 22%-69%). Lastly, intracranial PFS was 6.9 months (95% CI, 4.0-9.5).

Dato-DXd Safety

Any-grade treatment-related adverse events (TRAEs) occurred in 91% of patients with brain metastases at baseline, compared with 96% of those without, with grade 3 or higher TRAEs occurring in 23% and 32% of patients in the respective groups.

In patients with and without brain metastases at baseline, TRAEs led to dose reductions in 23% and 18%, respectively, dose delays in 17% and 24%, and treatment discontinuation in 4% and 6%. Serious TRAEs occurred in 8% of patients in both groups.

TROPION-Lung05 Trial

In the phase 2, multicenter, single-arm, open-label TROPION-Lung05 trial, 137 patients received 6 mg/kg Dato-DXd every 3 weeks.

Key eligibility criteria included stage IIIB, IIIC, or IV NSCLC; at least 1 actionable genomic alteration; ECOG performance status of 0 or 1; at least 1 line of targeted therapy; 1 or 2 prior cytotoxic agent-containing therapies including platinum-based therapy in the advanced/metastatic setting; and radiographic disease progression after the most recent therapy.

ORR by blind independent committee review (BICR) served as the primary end point. Secondary end points included duration of response, DCR, CBR, PFS, and time to response by BICR and investigator assessment, as well as confirmed ORR by investigator assessment, overall survival, safety, pharmacokinetics, and immunogenicity.

In this analysis, investigators focused on systemic efficacy and safety by central nervous system BICR baseline brain metastasis status and intracranial efficacy by mutation status.

Among those with and without brain metastases at baseline, median age was 58 years (range, 36-75) and 63 years (range, 29-79), respectively. The majority were women (53% vs 65%, respectively), Asian (55% vs 58%), had an ECOG performance score of 1 (64% vs 69%), and were never smokers (55% vs 56%).

Further, of those with and without baseline brain metastases, most had an EGFR mutation (55% vs 58%) or ALK rearrangement (28% vs 23%). In total, 72% of those with brain metastases at baseline had prior local therapy for their brain metastases, including radiation (59%), surgery (6%), and radiosurgery (23%).

Further Investigation

The median duration of treatment for those with baseline brain metastases was 3.2 months (range, 0.7-17.2) and 4.9 months (range, 0.7-20.6) for those without.

At data cutoff, 15% of patients with baseline brain metastases and 14% of patients without remained on study treatment. Disease progression (70% and 75%, respectively) was the most common reason for discontinued treatment.

“The data support further investigation of Dato-DXd in patients with brain [metastases],” the investigators concluded, adding that additional studies of the intracranial activity of the agent are ongoing, including the phase 2 TUXEDO-2 trial (NCT05866432) and the phase 2 DATO-BASE trial (NCT06176261).


Lisberg A, Ahn MJ, Kitazono S, et al. Intracranial efficacy of datopotamab deruxtecan (Dato-DXd) in patients (pts) with previously treated advanced/metastatic non-small cell lung cancer (a/m NSCLC) with actionable genomic alterations (AGA): Results from TROPION-Lung05. J Clin Oncol. 2024;42(suppl 16):abstr 8593. doi:10.1200/JCO.2024.42.16_suppl.8593.

Recent Videos
Although no responses were observed in 11 patients receiving abemaciclib monotherapy, combination therapies with abemaciclib may offer clinical benefit.
Findings show no difference in overall survival between various treatments for metastatic RCC previously managed with immunotherapy and TKIs.
An epigenomic profiling approach may help pick up the entire tumor burden, thereby assisting with detecting sarcomatoid features in those with RCC.
Future meetings may address how immunotherapy, bispecific agents, and CAR T-cell therapies can further impact the AML treatment paradigm.
Treatment with revumenib appeared to demonstrate efficacy among patients with KMT2A-rearranged acute leukemia in the phase 2 AUGMENT-101 study.
Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Data from the REVEAL study affirm elevated white blood cell counts and higher variant allele frequency as risk factors for progression in polycythemia vera.
Additional analyses of patient-reported outcomes and MRD status in the QuANTUM-First trial are also ongoing, says Harry P. Erba, MD, PhD.
Related Content